BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

57 related articles for article (PubMed ID: 10851492)

  • 1. Immunological implications of alterations in the c-Ki-ras and p53 genes in the stepwise progression of colorectal cancer: indications for the improvement of prognosis, biotherapy treatment and tumor biology understanding.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T ; Canossi A; Maccarone D; Papola F; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Dec; 12(6):385-93. PubMed ID: 10851492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Colon cancer and gene alterations: their immunological implications and suggestions for prognostic indices and improvements in biotherapy.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T; Adorno D
    Cancer Biother Radiopharm; 2006 Oct; 21(5):488-505. PubMed ID: 17105421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Necessity of biotherapeutic treatments inducing TH1 cell functions in colorectal cancer.
    Contasta I; Pellegrini P; Berghella AM; Del Beato T; Canossi A; Di Rocco M; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Dec; 11(6):373-83. PubMed ID: 10851498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. p53, Ki-ras, and DNA ploidy in human pancreatic ductal adenocarcinomas.
    Weyrer K; Feichtinger H; Haun M; Weiss G; Ofner D; Weger AR; Umlauft F; Grünewald K
    Lab Invest; 1996 Jan; 74(1):279-89. PubMed ID: 8569192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of the soluble CD30 serum level in colorectal cancer: a possible marker for a patient subset which could benefit from IL-2 biotherapy.
    Dle Beato T; Berghella AM; Pellegrini P; Domenico A; Casciani CU
    Cancer Biother Radiopharm; 1997 Oct; 12(5):297-304. PubMed ID: 10851480
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The sCEA molecule suppressive role in NK and TH1 cell functions in colorectal cancer.
    Pellegrini P; Berghella AM; Del Beato T; Maccarone D; Cencioni S; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1997 Aug; 12(4):257-64. PubMed ID: 10851473
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mutation analysis of p53, K-ras, and BRAF genes in colorectal cancer progression.
    Calistri D; Rengucci C; Seymour I; Lattuneddu A; Polifemo AM; Monti F; Saragoni L; Amadori D
    J Cell Physiol; 2005 Aug; 204(2):484-8. PubMed ID: 15702478
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Multiple molecular marker testing (p53, C-Ki-ras, c-erbB-2) improves estimation of prognosis in potentially curative resected non-small cell lung cancer.
    Schneider PM; Praeuer HW; Stoeltzing O; Boehm J; Manning J; Metzger R; Fink U; Wegerer S; Hoelscher AH; Roth JA
    Br J Cancer; 2000 Aug; 83(4):473-9. PubMed ID: 10945494
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detection of DCC and Ki-ras gene alterations in colorectal carcinoma tissue as prognostic markers for liver metastatic recurrence.
    Kato M; Ito Y; Kobayashi S; Isono K
    Cancer; 1996 Apr; 77(8 Suppl):1729-35. PubMed ID: 8608570
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of immunological evaluation in colorectal cancer.
    Berghella AM; Pellegrini P; Del Beato T; Maccarone D; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Dec; 11(6):355-61. PubMed ID: 10851496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD44 expression in colorectal adenomas is an early event occurring prior to K-ras and p53 gene mutation.
    Kim H; Yang XL; Rosada C; Hamilton SR; August JT
    Arch Biochem Biophys; 1994 May; 310(2):504-7. PubMed ID: 7513984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological directives for biotherapy improvement in the treatment of colorectal cancer.
    Pellegrini P; Berghella AM; Del Beato T; Adorno D; Casciani CU
    Cancer Biother Radiopharm; 1996 Apr; 11(2):113-8. PubMed ID: 10851527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of pre-treatment immunological parameters in colorectal cancer patients with unresectable metastases to the liver.
    Zaloudik J; Lauerova L; Janakova L; Talac R; Simickova M; Nekulova M; Mikulikova I; Kovarik J; Sheard M
    Hepatogastroenterology; 1999; 46(25):220-7. PubMed ID: 10228796
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ki-ras mutation and p53 overexpression predict the clinical behavior of colorectal cancer: a Southwest Oncology Group study.
    Ahnen DJ; Feigl P; Quan G; Fenoglio-Preiser C; Lovato LC; Bunn PA; Stemmerman G; Wells JD; Macdonald JS; Meyskens FL
    Cancer Res; 1998 Mar; 58(6):1149-58. PubMed ID: 9515799
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular events including p53 and k-ras alterations in the in vitro progression of a human colorectal adenoma cell line to an adenocarcinoma.
    Williams AC; Browne SJ; Yeudal WA; Paterson IC; Marshall CJ; Lane DP; Paraskeva C
    Oncogene; 1993 Nov; 8(11):3063-72. PubMed ID: 8414507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genetic alterations of human colorectal cancer].
    Suzuki T; Ishioka C; Gamo M; Niitani T; Shimodaira H; Kanbe M; Yamazaki T; Yusa Y; Kanamaru R
    Gan To Kagaku Ryoho; 1994 Feb; 21(3):343-50. PubMed ID: 8109990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ki-ras codon 12 point and P53 mutations: a molecular examination of the main tumor, liver, portal vein, peripheral arterial blood and para-aortic lymph node in pancreatic cancer.
    Yamaguchi K; Chijiiwa K; Torato N; Kinoshita M; Tanaka M
    Am J Gastroenterol; 2000 Aug; 95(8):1939-45. PubMed ID: 10950039
    [TBL] [Abstract][Full Text] [Related]  

  • 19. APC, K-ras, and p53 gene mutations in colorectal cancer patients: correlation to clinicopathologic features and postoperative surveillance.
    Hsieh JS; Lin SR; Chang MY; Chen FM; Lu CY; Huang TJ; Huang YS; Huang CJ; Wang JY
    Am Surg; 2005 Apr; 71(4):336-43. PubMed ID: 15943410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical and mutational analyses of beta-catenin, Ki-ras, and p53 in two subtypes of colorectal mucinous carcinoma.
    Ikeda S; Shimizu Y; Fujimori M; Ishizaki Y; Kurihara T; Ojima Y; Okajima M; Asahara T
    Clin Cancer Res; 2003 Nov; 9(15):5660-5. PubMed ID: 14654549
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.